SBHMY OTC
Sino Biopharmaceutical Limited
1W: +11.5%
1M: +26.9%
3M: +28.4%
YTD: -10.7%
1Y: -19.2%
3Y: +140.1%
5Y: +2.0%
$16.28
+1.78 (+12.28%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$76.1B
+16.3% ▲
5Y CAGR: +10.0%
Total Liabilities
$33.3B
+47.2% ▲
5Y CAGR: +6.1%
Shareholders Equity
$30.7B
-4.0% ▼
5Y CAGR: +12.9%
Cash & Investments
$22.6B
+54.6% ▲
5Y CAGR: +6.5%
Total Debt
$16.1B
+64.4% ▲
5Y CAGR: +2.5%
Net Debt
$8.7B
+3956.2% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $9.6B | $8.7B | $9.5B | $9.6B | $7.4B |
| Short-Term Investments | $6.2B | $8.3B | $1.6B | $5.0B | $15.2B |
| Cash & ST Investments | $15.8B | $16.9B | $14.1B | $14.6B | $22.6B |
| Net Receivables | $4.3B | $4.6B | $4.6B | $5.0B | $6.6B |
| Inventory | $1.9B | $2.3B | $2.0B | $2.4B | $2.3B |
| Other Current Assets | $1.3B | $1.6B | $2.5B | $251M | $3.0B |
| Total Current Assets | $23.5B | $25.9B | $23.8B | $24.7B | $34.5B |
| Property, Plant & Equip. | $8.5B | $9.3B | $9.9B | $10.3B | $10.2B |
| Goodwill & Intangibles | $1.7B | $1.9B | $929M | $3.1B | $7.1B |
| Long-Term Investments | $19.0B | $17.0B | $25.2B | $26.3B | $23.7B |
| Other Non-Current Assets | $7.5B | $9.5B | $3.8B | $1.0B | $56M |
| Total Non-Current Assets | $37.0B | $38.1B | $39.8B | $40.7B | $41.6B |
| Total Assets | $60.5B | $64.1B | $63.6B | $65.4B | $76.1B |
| — Liabilities — | |||||
| Accounts Payable | $1.8B | $1.9B | $1.3B | $1.5B | $1.5B |
| Short-Term Debt | $6.5B | $9.7B | $11.1B | $7.7B | $8.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.8B | $2.2B | $3.3B | $7.6B | $14.6B |
| Total Current Liabilities | $15.3B | $20.2B | $22.6B | $19.6B | $25.2B |
| Long-Term Debt | $5.2B | $3.9B | $1.1B | $2.0B | $7.6B |
| Other Non-Current Liab. | $381M | $131M | $125M | $997M | $165M |
| Total Non-Current Liabilities | $7.5B | $6.0B | $2.8B | $3.1B | $8.1B |
| Total Liabilities | $22.8B | $26.1B | $25.4B | $22.6B | $33.3B |
| — Equity — | |||||
| Common Stock | $415M | $415M | $415M | $414M | $414M |
| Retained Earnings | $27.2B | $23.1B | $23.6B | $25.3B | $0 |
| Accumulated OCI | -$9.2B | -$10.1B | -$9.9B | $0 | $0 |
| Total Stockholders Equity | $30.3B | $29.7B | $30.5B | $32.0B | $30.7B |
| Total Liabilities & Equity | $60.5B | $64.1B | $63.6B | $65.4B | $76.1B |
| — Key Metrics — | |||||
| Total Debt | $12.1B | $14.0B | $12.6B | $9.8B | $16.1B |
| Net Debt | $2.5B | $5.3B | $3.1B | $214M | $8.7B |
| Total Investments | $25.2B | $25.2B | $26.7B | $31.4B | $38.9B |